Trial Profile
Prospective Register Study to Record Safety and Efficacy of New Oral Anticoagulants
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 20 Jan 2023
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Edoxaban (Primary) ; Rivaroxaban (Primary)
- Indications Pulmonary embolism; Stroke; Venous thromboembolism
- Focus Adverse reactions; Therapeutic Use
- Acronyms DRESDEN NOAC RREGISTRY; NOAC
- Sponsors GWT-TUD GmbH
- 17 Jan 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2024.
- 17 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2024.
- 15 Mar 2022 Planned End Date changed from 1 Dec 2020 to 1 Dec 2022.